Member Info for Ralphiebabe

Recent ariticle from Dr Hitesh Mistry plus others.

https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.3165

After months of advertising the job position of PKPD modeller scientist on PYC site, yesterday, it was removed.

Merry Christmas and a Hppy and Healthy New Year.

Last end of year messages from Physiomics.

One on twitter,

2023 has been a year filled with growth, innovation & collaboration. Huge thanks to our wonderful partners, shareholders & incredible team. Looking forward to 2024 with enthusiasm!

https://x.com/Physiomics/status/1738174971531165906?s=20

Other on LinkedIn

And that’s a wrap! 🎉 2023 has been a year filled with growth, innovation and collaboration. From expanding our team to strengthening partnerships with some incredible companies united in our mission to drive advancements in #cancercare.

But none of this would be possible without the collaboration of our wonderful partners, shareholders, and incredible team. You all have been instrumental in making this possible, and we couldn't be more grateful. 🙏

As we step forward into 2024, we are excited about the many opportunities that lay ahead. Wishing everyone a Happy Christmas and a New Year filled with health and happiness

https://www.linkedin.com/posts/physiomics-plc_cancercare-pyc-2023highlights-activity-7143940401731706880-Ahe1?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy

Mentions diving into new scientific areas ??

Also, no mention of Dr Venkata Putcha as Head of Biostastics from RNS 3rd Oct, that’s 2 months, nothing on team page??

https://x.com/Physiomics/status/1737138190140518445?s=20

The funding allocated is as per RNS on 10th November, not new funding.

Hi Laura,

Depends on the details of the contract between Pyc and Ankyra.

Also, if model progresses further.

Pyc just put out tweet about the Ankyra abstract at AACR 2023.

The latest updated abstract has following at end of “conclusion”.

The model could potentially form the basis of a translational model to assist in designing first-in-man dose and schedule.

MANK-101 abstract 141 from December 1st 2023.

https://aacrjournals.org/mct/article/22/12_Supplement/A141/730575/Abstract-A141-Preclinical-pharmacokinetic-PK-and

Spacex Starship planned liftoff same time as Pyc presentation, will there be a liftoff for either?

https://www.youtube.com/live/mhJRzQsLZGg?si=7cZ6FCuuZyyslntI

Https://www.linkedin.com/posts/physiomics-plc_bioeurope2023-activity-7130187218320543744-BVfz?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy

Was following a play on words?

A huge thanks to everyone we met at BIOEurope in Munich last week! Networking & partnering was a success and we can't wait to continue the conversations

Https://www.physiomics.co.uk/wp-content/uploads/2023/10/Physiomics-Annual-Report-2023-final-print.pdf

Mentions Going forward into Biostatistics a few times.

Pages 6,7 and 10.

We're excited to announce that we've moved into our brand new office at

@MiltonPark's Bee House! With its convenient links to Oxford & London, plus its flexible working environment, it's the perfect place to continue pursuing our growth aspirations.

How long will it take???

Https://ankyratx.com/wp-content/uploads/2023/10/PYC_EORTC_Poster_2023_FINAL.pdf

Wonder if results will be published on same day?

Dr Christophe Chassagnole will be attending Bioforward 2023 on 26 Sept.

https://x.com/Physiomics/status/1702306107786404234?s=20

Https://uk.linkedin.com/in/peter-sargent-718085a

Last sentence interesting, (emerging to top-tier).

About

A senior life sciences professional with extensive commercial, scientific, operational and leadership expertise within drug and diagnostic development. Significant experience spanning the full breadth of R&D, as well as leading commercial and operation strategy in high growth businesses and governmental organisations. Now working within a management consultancy practice supporting biopharma (emerging to top-tier) across their R&D with organisation, process and technology transformation.

This is not a large contract financially.

This RNS issued as a RNSNON (RnsReach), not a regulatory RNS (UKREG).

What is RNS Reach?

RNS Reach is an extension of RNS and delivers non-price sensitive information. It is used by companies to keep in contact with investors and can include marketing messages, as well as product information for commercial purposes.

What information appears on RNS Reach?

Intention to float on AIM (the main market is done on RNS)

Launches of websites and product launches

Company presentations and upcoming investor webinars or events

New contracts that are not price-sensitive

Acknowledgements by a professional association

Company getting up to date on abstracts from a AACR 2018 and 2021.

https://www.researchgate.net/profile/Frances-Brightman-2

These days I just wait for official notices of what is happening with company, before deciding if to plough any money back into it.

In past, I thought I knew what direction company was going in, and it cost me.

Not sure if any reverence to Pyc, but new employee David Hodson and Hitesh Mistry, with others, has recently published a paper on “ Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimisa in MC38 Syngeneic Tumours via Modelling and Simulation”

https://pubmed.ncbi.nlm.nih.gov/37348964/

Lea Sta now added to team profile.

https://www.physiomics.co.uk/about/team/